Gilead Sciences, Inc. CEO Net Worth

Last Updated Mar 10, 2025
CEO NameDaniel O'Day
NationalityUnited States
Net Worth Estimation$120 million

Daniel O'Day's estimated net worth of around $120 million is primarily due to his compensation as CEO of Gilead Sciences, Inc., including annual salary, stock options, and performance-based bonuses since joining in 2019. His accumulated wealth also reflects substantial equity grants and long-term incentive awards tied to the company's stock performance.

Daniel O'Day's estimated net worth of $120,000,000 is 33% higher than the maximum CEO net worth range ($90,000,000) typically observed in the healthcare industry. This places him significantly above both the minimum and maximum estimated CEO net worth benchmarks for the sector.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Daniel O'Day Performance in Gilead Sciences, Inc.

Daniel O'Day, CEO of Gilead Sciences, Inc., demonstrates strategic leadership by driving innovation in antiviral therapies and expanding the company's oncology portfolio. His decision-making emphasizes rapid response to global health crises, notably accelerating COVID-19 treatment development and ensuring robust pipeline diversification. Under O'Day's performance-focused leadership, Gilead experienced sustained revenue growth and strengthened its position as a leader in biopharmaceuticals.


Latest News

Gilead Sciences and CEO Daniel O'Day Lead with Innovation and Strategic Growth in 2025

Gilead Sciences entered a strategic partnership with LEO Pharma to develop oral STAT6 inhibitors for inflammatory diseases and won the prestigious 2025 Prix Galien USA Award for Yeztugo, a novel HIV prevention drug. CEO Daniel O'Day highlighted the scientific innovation and potential public health impact of their HIV treatment during recent interviews and company announcements.
Source: http://www.gilead.com/news/news-details/2025/gilead-sciences-wins-prestigious-2025-prix-galien-usa-award-for-best-pharmaceutical-product-with-yeztugo-lenacapavir



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Gilead Sciences, Inc. are subject to change from time to time.

Comments

No comment yet